Prolactin: A diabetogenic hormone
Open accessAbstract
During an oral glucose tolerance test (OGTT) glucose and insulin levels were measured in 26 patients with prolactin-producing pituitary tumours without growth hormone excess. Basal glucose and insulin levels did not differ from the values of an age-matched control group. After glucose load the hyperprolactinaemic patients showed a decrease in glucose tolerance and a hyperinsulinaemia. Bromocriptine (CB 154), which suppressed PRL, improved glucose tolerance and decreased insulin towards normal in second OGTT. Human PRL or CB 154 had no significant influence on insulin release due to glucose in the perfused rat pancreas. These findings suggest a diabetogenic effect of PRL. CB 154 might be a useful drug in improving glucose utilization in hormone-active pituitary tumours.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Immunoassay of insulin with insulin-antibody precipitate
Hales, C. N., & Pj, R. (1963) · Biochemical Journal · doi:10.1042/bj0880137 · Cited by 2,640 · see citing works
A Homologous Radioimmunoassay for Human Prolactin1
SINHA, Y. N., SELBY, F. W., LEWIS, U. J., & VANDERLAAN, W. P. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-3-509 · Cited by 650 · see citing works
Insulin Hypersensitivity and Physiological Insulin Antagonists
de Bodo, R. C., & ALTSZULER, N. (1958) · Physiological Reviews · doi:10.1152/physrev.1958.38.3.389 · Cited by 226 · see citing works
Bromocriptine treatment of acromegaly.
Thorner, M. O., Chait, A., Aitken, M., et al. (1975) · BMJ · doi:10.1136/bmj.1.5953.299 · Cited by 203 · see citing works
Herington, A. C., Jacobs, L. S., & Daughaday, W. H. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-2-257 · Cited by 83 · see citing works
Landgraf, R., Kotler-Brajtburg, J., & Matschinsky, F. M. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.3.536 · Cited by 61 · see citing works
Self-citationManns, J. G., & Boda, J. M. (1965) · Endocrinology · doi:10.1210/endo-76-6-1109 · Cited by 58 · see citing works
EFFECT OF BROMOCRIPTIN ON THE ENDOCRINE SYSTEM AND FETAL DEVELOPMENT
del Pozo, E., Darragh, A., Lancranjan, I., et al. (1977) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1977.tb03338.x · Cited by 31 · see citing works
Effect of Ovine Prolactin Administration on Glucose Metabolism and Plasma Insulin Levels in the Dog
Rathgeb, I., Winkler, B., Steele, R., et al. (1971) · Endocrinology · doi:10.1210/endo-88-3-718 · Cited by 31 · see citing works
Evidence for ‘big’ and ‘little’ components of circulating immunoreactive prolactin in humans
von Werder, K., & Clemm, C. (1974) · FEBS Letters · doi:10.1016/0014-5793(74)80454-0 · Cited by 28 · see citing works
Effect of Ovine Prolactin Administration on Free Fatty Acid Metabolism in the Normal Dog
Winkler, B., Rathgeb, I., Steele, R., et al. (1971) · Endocrinology · doi:10.1210/endo-88-6-1349 · Cited by 22 · see citing works
Methoden der Harn- und Blutzuckerbestimmung
Schmidt, F. H. (1971) · Springer eBooks · doi:10.1007/978-3-642-47669-3_36 · Cited by 19 · see citing works
Berle, P., Finsterwalder, E., & Apostolakis, M. (1974) · Hormone and Metabolic Research · doi:10.1055/s-0028-1093823 · Cited by 15 · see citing works
CEROSI, E., Li, C. H., & Luft, R. (1972) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-34-4-644 · Cited by 15 · see citing works
Renauld, A., Sverdlik, R. C., & Andrade, L. L. D. A. (1973) · Acta Diabetologica · doi:10.1007/bf02590715 · Cited by 9 · see citing works
Prolactin as an insulin antagonist
Sinkoff, M. W., & de Bodo, R. C. (1953) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00246255 · Cited by 8 · see citing works
[Diminished glucose tolerance and hyperinsulinism due to prolactin secreting adenoma].
TOURNIAIRE, J., Pallo, D., Pousset, G., et al. (1974) · PubMed · Cited by 8 · see citing works
Lostroh, A. J. (1974) · European Journal of Endocrinology · doi:10.1530/acta.0.0770096 · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Adamson, U., Cerasi, E.: Time-bound effects of exogenous human growth hormone and glucose induced insulin release in man. VIII. Congr. of Int. Diabetes Fed. 1973, Excerpta med. (Amst.), Intern. Congr. Series 280, 30 (1973)
- del Pozo, E., Burmeister, P., Darragh, A., Lankranjan, E.: Endocrine profile of CB 154: action on fetal endocrine devel- opment. J. Clin. Endocrinol. (in press)
Cited by
Sorted by citations
Combs, T. P., Berg, A. H., Rajala, M. W., Klebanov, S., Iyengar, P., Jimenez-Chillaron, J. C., Patti, M. E., Klein, S. L., Weinstein, R. S., & Scherer, P. E. (2003) · Diabetes · doi:10.2337/diabetes.52.2.268 · Cited by 544 · see citing works
Nilsson, L., Binart, N., Bohlooly-Y, M., Bramnert, M., Egecioglu, E., Kindblom, J., Kelly, P. A., Kopchick, J. J., Ormandy, C. J., Ling, C., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.04.026 · Cited by 191 · see citing works
Brelje, T. C., Stout, L. E., Bhagroo, N. V., & Sorenson, R. L. (2004) · Endocrinology · doi:10.1210/en.2004-0201 · Cited by 134 · see citing works
Inancli, S. S., Usluogullari, A., Ustu, Y., Caner, S., Tam, A. A., Ersoy, R., & Cakir, B. (2013) · Endocrine · doi:10.1007/s12020-012-9857-y · Cited by 59 · see citing works
Laway, B., Pala, N., Misgar, R., Shah, Z., Gojwari, T., & Dar, T. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176346 · Cited by 21 · see citing works
“There is limited data on the body fat distribution in patients with HPL, though some studies have demonstrated higher body fat mass in patients with HPL in the presence of high prevalence of obesity.[21] Our study results revealed higher trunk fat mass in patients compared to BMI‐matched control population, without a…”
Result
- Authors
- Landgraf, R., Landgraf-Leurs, M. M. C., Weissmann, A., Hörl, R., von Werder, K., & Scriba, P. C.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Venue
- Diabetologia
- Published
- 1977-04
- Volume
- 13
- Issue
- 2
- Pages
- 99-104
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1970595886
- Cited by
- 167
- References
- 18
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 9 · 2023: 3 · 2022: 7 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 5 · 2013: 4 · 2012: 3
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- prolactin, diabetogenic effect, prolactinoma, hyperprolactinemia, glucose tolerance, hyperinsulinemia, bromocriptine, insulin secretion, pancreatic islets, pituitary tumors
- MeSH terms
- Insulin Secretion, Adenoma, Adult, Animals, Blood Glucose, Bromocriptine, Female, Glucose Tolerance Test, Humans, Insulin, Male, Middle Aged, Pituitary Neoplasms, Prolactin, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
